A 12-week clinical trial of talsaclidine, a muscarinic agonist, in the treatment of mild to moderate Alzheimer's disease

被引：0
|
作者：
Jones, R
Raschig, A
Müller, A
Müller, S
Ingelheim, B
机构：
[1] Res Inst Care Elderly, Bath, Somerset, England
[2] Boehringer Ingelheim Pharma KG, Biberach, Germany
来源：
NEUROBIOLOGY OF AGING | 2002年 / 23卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
462
引用
收藏
页码：S122 / S122
页数：1
相关论文
共 50 条
  • [21] Nicergoline in the treatment of mild-to-moderate Alzheimer's disease - A European multicentre trial
    Winblad, B
    Bonura, ML
    Rossini, BM
    Battaglia, A
    CLINICAL DRUG INVESTIGATION, 2001, 21 (09) : 621 - 632
  • [22] Treatment with Cerebrolysin, donepezil and a combination therapy in mild to moderate Alzheimer's disease: a double-blind clinical trial
    Alvarez, A.
    Sampedro, C.
    Couceiro, V.
    Cacabelos, R.
    Garcia-Fantini, M.
    Aleixandre, M.
    Linares, C.
    Granizo, E.
    Doppler, E.
    Novak, P.
    Moessler, H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 : 342 - 342
  • [23] Solanezumab for the treatment of mild-to-moderate Alzheimer's disease
    Imbimbo, Bruno P.
    Ottonello, Simone
    Frisardi, Vincenza
    Solfrizzi, Vincenzo
    Greco, Antonio
    Seripa, Davide
    Pilotto, Alberto
    Panza, Francesco
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2012, 8 (02) : 135 - 149
  • [24] Memantine in the treatment of mild-to-moderate Alzheimer's disease
    Cosman, Kelly M.
    Boyle, Llsa L.
    Porsteinsson, Anton P.
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (02) : 203 - 214
  • [25] Intravenous immunoglobulin for treatment of mild to moderate Alzheimer's disease
    Laffman-Johnson, Elise
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 (06) : 461 - 461
  • [26] Economic and clinical benefits of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population: A 52-week prospective study
    Suh, Guk-Hee
    Jung, Hee Yeon
    Lee, Chang Uk
    Choi, Sungku
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2008, 23 (01) : 10 - 17
  • [27] Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease
    不详
    JOURNAL OF NEUROLOGY, 2018, 265 (09) : 2163 - 2163
  • [28] Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease
    Egan, Michael F.
    Kost, James
    Tariot, Pierre N.
    Aisen, Paul S.
    Cummings, Jeffrey L.
    Vellas, Bruno
    Sur, Cyrille
    Mukai, Yuki
    Voss, Tiffini
    Furtek, Christine
    Mahoney, Erin
    Mozley, Lyn Harper
    Vandenberghe, Rik
    Mo, Yi
    Michelson, David
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (18): : 1691 - 1703
  • [29] Preservation of cortical metabolic function by donepezil in patients with mild to moderate Alzheimer's disease: A 24-week clinical trial with placebo control
    Moeller, JR
    Rusinek, H
    Casanova, MF
    Hoffman, JM
    Tune, LM
    Perdomo, C
    Ieni, JR
    Jewart, RD
    Cooper, TB
    NEUROPSYCHOPHARMACOLOGY, 2004, 29 : S190 - S191
  • [30] Misplacing objects in mild to moderate Alzheimer's disease: a descriptive analysis from the VISTA clinical trial
    Hamilton, L.
    Fay, S.
    Rockwood, K.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2009, 80 (09): : 960 - 965
12345